Download PDF
Aktuelle Urol 2012; 43(3): 168-176
DOI: 10.1055/s-0031-1284023
Uroonkologie
© Georg Thieme Verlag KG Stuttgart · New York

Supportion in der urologischen Tumortherapie

Supportive Options in the Treatment of Urological Tumours
B. J. Schmitz-Dräger    *
1   Urologie, EuromedClinic, Fürth
2   Urologische Klinik, Klinikum Hohe Warte, Bayreuth
,
E. Bismarck    *
1   Urologie, EuromedClinic, Fürth
,
C. Fischer
2   Urologische Klinik, Klinikum Hohe Warte, Bayreuth
,
und die Mitglieder des Arbeitskreises Prävention, Umwelt und Komplementärmedizin (PUK) › Author Affiliations
Further Information

Publication History

Publication Date:
25 May 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die zunehmende Alterung der Gesellschaft mit einer entsprechenden Zunahme urologischer Tumorerkrankungen sowie gravierende Veränderungen in der systemischen Behandlung von Malignomen führen dazu, dass supportiven Maßnahmen eine immer größere Bedeutung zukommt. Während die Behandlung (Operation, Chemotherapie, Strahlentherapie) zunehmend standardisiert erfolgt, gilt dies für die Supportion längst nicht in gleichem Umfang. Gerade eine effektive Supportion ist jedoch notwendige Voraussetzung für eine erfolgreiche systemische Behandlung. In der vorliegenden Übersicht sind die wichtigsten Nebenwirkungen einer systemischen Behandlung urologischer Tumore beschrieben und ihre Behandlung in kurzer, praxisnaher Form zusammengefasst. Dabei wurde Wert darauf gelegt, soweit als möglich Evidenz-basierte Behandlungsempfehlungen zu geben.

Abstract

An ageing society with a consecutive increase of genitourinary malignancies along with remarkable changes in systemic cancer therapy provide the basis for an increasing role of supportive measures. While surgical treatment, radiation or chemotherapy are undergoing subsequent standardisation, supportive measures are still widely used on the basis of personal experience alone. However, effective support is the prerequisite for a successful systemic treatment. Within this review the most relevant side effects of systemic therapy for urological tumors are summarised and the respective therapeutic options are presented in a brief but practice-oriented way. The authors have aimed at the consideration of evidence-based measures, wherever possible.

Schlüsselwörter

urologische Tumore - Supportion - Erbrechen - neutropenisches Fieber - Knochen-bezogene Ereignisse

Key words

urological malignancies - supportive therapy - nausea - neutropenic fever - skeletal-related events

 * gleichwertiger Beitrag bei Erarbeitung und Abfassen des Manuskriptes


** Mitglieder des AK PUK sind: J. Altwein, München; C. Fischer, Bayreuth; T. Klotz, Amberg; G. Lümmen, Troisdorf; M. J. Mathers, Remscheid; V. Rohde, Bad Schwartau; R. Schaefer, Bonn; B. J. Schmitz-Dräger, Fürth; F. Sommer, Hamburg; A. Schroeder, Neumünster; P. Thelen, Göttingen


 

  • Literatur

  • 1 http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
    PubMed
  • 2 Johansson JE, Wersall P, Brandberg Y et al. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer – a randomized study. Scand J Urol Nephrol 2001; 35: 288-294
    CrossrefPubMedGoogle Scholar
  • 3 Winquist E, Julian JA, Moore MJ et al. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia. J Clin Oncol 2009; 27: 644-646
    PubMedGoogle Scholar
  • 4 Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a metaanalysis of randomised trials. Lancet 2009; 373: 1532-1542
    CrossrefPubMedGoogle Scholar
  • 5 Wirth M, Weißbach L, Albrecht C et al. (Hrsg.) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Düsseldorf, Berlin: 2011 Version 2.0, Aktualisierung 2011
    PubMedGoogle Scholar
  • 6 Link H, Bohme A, Cornely OA et al. Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO); Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society) Antimicrobial therapy of unexplained fever in neutropenic patients – Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Antimicrobial therapy of unexplained fever in neutropenic patients – Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82: 105-117
    CrossrefPubMedGoogle Scholar
  • 7 Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology 2000; 18: 3038-3051
    PubMedGoogle Scholar
  • 8 Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32
    PubMedGoogle Scholar
  • 9 Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189-4198
    CrossrefPubMedGoogle Scholar
  • 10 Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol 2008; 1 (Suppl. 02) ii122-ii125
    PubMedGoogle Scholar
  • 11 Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109 (05) 820-831
    CrossrefPubMedGoogle Scholar
  • 12 Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev; 19.04.2006 CD000978
    PubMedGoogle Scholar
  • 13 Denton A, Forbes A, Andreyev J et al. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev; 2002 CD003455
    PubMedGoogle Scholar
  • 14 McGough C, Baldwin C, Frost G et al. Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy. Br J Cancer 2004; 90: 2278-2287
    PubMedGoogle Scholar
  • 15 Sanguineti G, Franzone P, Marcenaro M et al. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. Strahlenther Onkol 2003; 179: 464-470
    PubMedGoogle Scholar
  • 16 Sherman DM, Mangini L, Poirier P et al. Double-blind comparison of loperamide and placebo in the treatment of radiation-induced diarrhea. Adv Ther 1989; 6: 103-111
    PubMedGoogle Scholar
  • 17 Giralt J, Regadera JP, Verges R et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008; 71: 1213-1219
    CrossrefPubMedGoogle Scholar
  • 18 Scotte F, Tourani JM, Banu E et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23: 4424-4429
    CrossrefPubMedGoogle Scholar
  • 19 Scotte F, Banu E, Medioni J et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008; 112: 1625-1631
    CrossrefPubMedGoogle Scholar
  • 20 Anderson R, Jatoi A, Robert C et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14 (03) 291-302
    CrossrefPubMedGoogle Scholar
  • 21 Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011; 6 (04) 235-243
    CrossrefPubMedGoogle Scholar
  • 22 Tyrrell C. Immediate Treatment with Bicalutamide, 150 mg / d Following Radiotherapy in Localized or Locally Advanced Prostate Cancer. Rev Urol 2004; 6 (Suppl. 02) 29-36
    PubMedGoogle Scholar
  • 23 Perdona S, Autorino R, De PS et al. Efficacy of tamoxifen and radiotherapy for prevention andtreatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005; 6: 295-300
    CrossrefPubMedGoogle Scholar
  • 24 Irani J, Salomon L, Oba R et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11: 147-154
    CrossrefPubMedGoogle Scholar
  • 25 Spetz AC, Zetterlund EL, Varenhorst E et al. Incidence and management of hot flashes in prostate cancer. J Support Oncol 2003; 1: 263-270
    PubMedGoogle Scholar
  • 26 Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998-2006
    CrossrefPubMedGoogle Scholar
  • 27 Sandhu SS, Goldstraw M, Woodhouse CR. The management of haemorrhagic cystitis with sodium pentosan polysulphate. BJU Int 2004; 94: 845-847
    CrossrefPubMedGoogle Scholar
  • 28 Toren PJ, Norman RW. Cyclophosphamide induced hemorrhagic cystitis successfully treated with pentosanpolysulphate. J Urol 2005; 173: 103
    CrossrefPubMedGoogle Scholar
  • 29 Dawson TE, Jamison J. Intravesical treatments for painful bladder syndrome / interstitial cystitis. Cochrane Database Syst Rev; 17.10.2007 CD006113
    PubMedGoogle Scholar
  • 30 Davis M, MacDonald H, Sames C et al. Severe cyclophosphamide-induced haemorrhagic cystitis treated with hyperbaric oxygen. N Z Med J 2011; 124 (1340) 48-54
    PubMedGoogle Scholar
  • 31 Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-1295
    CrossrefPubMedGoogle Scholar
  • 32 Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46
    CrossrefPubMedGoogle Scholar
  • 33 Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468
    CrossrefPubMedGoogle Scholar
  • 34 Saad F, Chen YM, Gleason DM et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007; 5: 390-396
    CrossrefPubMedGoogle Scholar
  • 35 Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822
    CrossrefPubMedGoogle Scholar
  • 36 Sze WM, Shelley M, Held I et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy – a systematic review of the randomised trials. Cochrane Database Syst Rev; 2011 CD004721
    PubMedGoogle Scholar
  • 37 Patchell RA, Tibbs PA, Regine WF et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366: 643-648
    CrossrefPubMedGoogle Scholar
  • 38 Bauman G, Charette M, Reid R et al. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol 2005; 75: 258-270
    PubMedGoogle Scholar
  • 39 Parker C, Heinrich D, O’Sullivan JM et al. Overall survival benefit and safety profile of Radium-223 Chloride (Alfaradin), a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. San Francisco: Annual Meeting of the GU ASCO. 2.–4.2.1012
    PubMedGoogle Scholar
  • 40 Dearnaley DP, Mason MD, Parmar MK et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009; 10: 872-876
    CrossrefPubMedGoogle Scholar
  • 41 Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev; 19.07.2006 CD005037 3.
    PubMedGoogle Scholar
  • 42 Aveyard P, Adab P, Cheng KK et al. Does smoking status influence the prognosis of bladder cancer? A systematic review.. BJU Int 2002; 90 (03) 228-239
    CrossrefPubMedGoogle Scholar
  • 43 Giovannucci E, Rimm EB, Ascherio A et al. Smoking and risk of total and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomarkers Prev 1999; 8: 277-282
    PubMedGoogle Scholar
  • 44 McMillan EM, Newhouse IJ. Exercise is an effective treatment modality for reducing cancer-related fatigue and improving physical capacity in cancer patients and survivors: a meta-analysis. Appl Physiol Nutr Metab 2011; 36: 892-903
    CrossrefPubMedGoogle Scholar
  • 45 Herrstedt J, Roila F. ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2009; 20 (Suppl. 04) 156-158
    PubMedGoogle Scholar